Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | CNR2 | P34972 | 3/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.35 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.33 |
| ▸ | SLC18A3 | Q16572 | 2/20 | 0.32 |
| ▸ | DRD2 | P14416 | 1/20 | 0.30 |
| ▸ | DRD3 | P35462 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23231154 | 1.00 | ALDH1A1 (0.36) | ALDH1A1CNR2HRH3HSD11B1SLC18A3 | |
| SCHEMBL12869723 | 1.00 | ALDH1A1 (0.36) | ALDH1A1CNR2HRH3HSD11B1SLC18A3 | |
| SCHEMBL17345123 | 1.00 | ALDH1A1 (0.36) | ALDH1A1CNR2HRH3HSD11B1SLC18A3 | |
| SCHEMBL20364750 | 1.00 | ALDH1A1 (0.36) | ALDH1A1CNR2HRH3HSD11B1SLC18A3 | |
| SCHEMBL13910210 | 1.00 | ALDH1A1 (0.36) | ALDH1A1CNR2HRH3HSD11B1SLC18A3 | |
| SCHEMBL20078451 | 0.98 | SLC18A3 (0.35) | ALDH1A1CNR2HRH3HSD11B1SLC18A3 | |
| SCHEMBL20696685 | 0.98 | SLC18A3 (0.35) | ALDH1A1CNR2HRH3HSD11B1SLC18A3 | |
| SCHEMBL2741649 | 0.95 | CNR2 (0.33) | ALDH1A1CNR2HRH3DRD2DRD3 | |
| SCHEMBL21477613 | 0.91 | HRH3 (0.33) | ALDH1A1HRH3 | |
| SCHEMBL21476719 | 0.91 | HRH3 (0.33) | ALDH1A1HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 118 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240239811-A1 | 5-(5-(PIPERIDIN-4-YL)THIENO[3,2-C]PYRAZOL-2-YL]INDAZOLE DERIVATIVES AND RELATED COMPOUNDS AS MODULATORS FOR SPLICING NUCLEIC ACIDS AND FOR THE T | REMIX THERAPEUTICS INC. | 2024-07-18 | — | — | US | disclosed |
| US-11912714-B2 | Spiropyrrolidine derived antiviral agents | ENANTA PHARMACEUTICALS, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| US-11912714-B2 | Spiropyrrolidine derived antiviral agents | ENANTA PHARMACEUTICALS, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| US-11858945-B2 | Alkyne-containing antiviral agents | ENANTA PHARMACEUTICALS, INC. (US) | 2024-01-02 | — | — | US | disclosed |
| US-20230365566-A1 | HETEROCYCLIC AMIDES AND THEIR USE FOR MODULATING SPLICING | REMIX THERAPEUTICS INC. | 2023-11-16 | — | — | US | disclosed |
| US-20230365526-A1 | PYRIDAZINE DERIVATIVES FOR MODULATING NUCLEIC ACID SPLICING | REMIX THERAPEUTICS INC (US) | 2023-11-16 | — | — | US | disclosed |
| US-20230219979-A1 | PYRAZOLO[1,5-a]PYRIDINE COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | SHENZHEN ZHONGGE BIOLOGICAL TECHNOLOGY CO., LTD. (CN) | 2023-07-13 | — | — | US | disclosed |
| US-20230219979-A1 | PYRAZOLO[1,5-a]PYRIDINE COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | SHENZHEN ZHONGGE BIOLOGICAL TECHNOLOGY CO., LTD. (CN) | 2023-07-13 | — | — | US | disclosed |
| US-20230212164-A1 | ANNULATED 2-AMINO-3-CYANO THIOPHENES AND DERIVATIVES FOR THE TREATMENT OF CANCER | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2023-07-06 | — | — | US | disclosed |
| EP-3897855-B1 | KIF18A INHIBITORS | AMGEN INC (US) | 2023-06-07 | — | — | EP | disclosed |
| US-20070207995-A1 | Deazapurines useful as inhibitors of Janus kinases | VERTEX PHARMACEUTICALS INCORPORATED | 2007-09-06 | — | — | US | disclosed |
| US-20070197628-A1 | Cannabinoid receptor modulators | INTERVET INTERNATIONAL B.V. (NL) | 2007-08-23 | — | — | US | disclosed |
| US-20070197628-A1 | Cannabinoid receptor modulators | INTERVET INTERNATIONAL B.V. (NL) | 2007-08-23 | — | — | US | disclosed |
| US-7256186-B2 | Gamma secretase inhibitors | SCHERING CORPORATION (US) | 2007-08-14 | — | — | US | disclosed |
| US-20070135466-A1 | Pyrrolopyridines useful as inhibitors of protein kinase | VERTEX PHARMACEUTICALS INCORPORATED | 2007-06-14 | — | — | US | disclosed |
| US-7208602-B2 | Gamma secretase inhibitors | SCHERING CORPORATION (US) | 2007-04-24 | — | — | US | disclosed |
| US-7208602-B2 | Gamma secretase inhibitors | SCHERING CORPORATION (US) | 2007-04-24 | — | — | US | disclosed |
| US-20070043063-A1 | Such as 3-(2-Methanesulfonyl-pyrimidin-4-yl)-5-pyridin-3-yl-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridine; heart disease, diabetes, Alzheimer's disease, immunodeficiency disorders, inflammatory diseases, hypertension, allergic diseases, autoimmune diseases, destructive bone disorders | VERTEX PHARMACEUTICALS INCORPORATED | 2007-02-22 | — | — | US | disclosed |
| US-20050085506-A1 | Novel gamma secretase inhibitors | SCHERING-PLOUGH CORPORATION AND PHARMACOPEIA, INC. | 2005-04-21 | — | — | US | disclosed |
| US-20040171614-A1 | Novel gamma secretase inhibitors | SCHERING-PLOUGH CORPORATION | 2004-09-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040171614-A1 | Novel gamma secretase inhibitors | BACE1, BACE2, APP | ALDH1A1 4012/4885CNR2 361/4885HRH3 789/4885 |
| US-20230365566-A1 | HETEROCYCLIC AMIDES AND THEIR USE FOR MODULATING SPLICING | RBM17, HNRNPA1, HNRNPAB | ALDH1A1 1569/4885CNR2 4297/4885HRH3 3789/4885 |
| US-20230219979-A1 | PYRAZOLO[1,5-a]PYRIDINE COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | RET, GRK4, RIN1 | ALDH1A1 1772/4885CNR2 3791/4885HRH3 1429/4885 |
| US-20070043063-A1 | Such as 3-(2-Methanesulfonyl-pyrimidin-4-yl)-5-pyridin-3-yl-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridine; heart disease, diabetes, Alzheimer's disease, immunodeficiency disorders, inflammatory diseases, hypertension, allergic diseases, autoimmune diseases, destructive bone disorders | LCK, PDXK, CHUK | ALDH1A1 3821/4885CNR2 1386/4885HRH3 605/4885 |
| US-20070197628-A1 | Cannabinoid receptor modulators | CNR1, CNR2, GPR18 | ALDH1A1 1999/4885CNR2 2/4885HRH3 779/4885 |
| US-11912714-B2 | Spiropyrrolidine derived antiviral agents | ACE, ACE2, PKD1 | ALDH1A1 319/4885CNR2 2978/4885HRH3 4059/4885 |
| US-20070135466-A1 | Pyrrolopyridines useful as inhibitors of protein kinase | JAK2, JAK1, JAK3 | ALDH1A1 4036/4885CNR2 3901/4885HRH3 3011/4885 |
| US-20230365526-A1 | PYRIDAZINE DERIVATIVES FOR MODULATING NUCLEIC ACID SPLICING | SNRPA, RBM17, SNRPB2 | ALDH1A1 3247/4885CNR2 4582/4885HRH3 3334/4885 |
| US-20070207995-A1 | Deazapurines useful as inhibitors of Janus kinases | JAK1, JAK3, JAK2 | ALDH1A1 2028/4885CNR2 3988/4885HRH3 2582/4885 |
| US-20230212164-A1 | ANNULATED 2-AMINO-3-CYANO THIOPHENES AND DERIVATIVES FOR THE TREATMENT OF CANCER | RSU1, KRAS, NRAS | ALDH1A1 2334/4885CNR2 1087/4885HRH3 2569/4885 |
| US-11858945-B2 | Alkyne-containing antiviral agents | ACE, SARS1, ACE2 | ALDH1A1 876/4885CNR2 2724/4885HRH3 2484/4885 |
| US-20050085506-A1 | Novel gamma secretase inhibitors | BACE1, BACE2, APP | ALDH1A1 2742/4885CNR2 370/4885HRH3 278/4885 |
| US-20240239811-A1 | 5-(5-(PIPERIDIN-4-YL)THIENO[3,2-C]PYRAZOL-2-YL]INDAZOLE DERIVATIVES AND RELATED COMPOUNDS AS MODULATORS FOR SPLICING NUCLEIC ACIDS AND FOR THE T | HNRNPAB, HNRNPC, HNRNPA1 | ALDH1A1 959/4885CNR2 4387/4885HRH3 2812/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.